Xponance Inc. Has $10.37 Million Stock Holdings in McKesson Co. (NYSE:MCK)

Xponance Inc. trimmed its position in shares of McKesson Co. (NYSE:MCK) by 11.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 22,400 shares of the company’s stock after selling 3,022 shares during the quarter. Xponance Inc.’s holdings in McKesson were worth $10,371,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. AIA Group Ltd purchased a new stake in shares of McKesson during the fourth quarter worth $1,574,000. Wright Investors Service Inc. raised its holdings in McKesson by 39.6% during the fourth quarter. Wright Investors Service Inc. now owns 5,902 shares of the company’s stock valued at $2,733,000 after buying an additional 1,673 shares in the last quarter. HF Advisory Group LLC raised its holdings in McKesson by 21.0% during the fourth quarter. HF Advisory Group LLC now owns 646 shares of the company’s stock valued at $299,000 after buying an additional 112 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt grew its position in shares of McKesson by 1.4% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 8,582 shares of the company’s stock valued at $3,973,000 after purchasing an additional 119 shares during the last quarter. Finally, KLCM Advisors Inc. grew its position in shares of McKesson by 15.0% in the fourth quarter. KLCM Advisors Inc. now owns 630 shares of the company’s stock valued at $292,000 after purchasing an additional 82 shares during the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other McKesson news, EVP Leann B. Smith sold 186 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total transaction of $92,256.00. Following the completion of the sale, the executive vice president now owns 1,511 shares in the company, valued at approximately $749,456. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other McKesson news, EVP Leann B. Smith sold 186 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total transaction of $92,256.00. Following the completion of the sale, the executive vice president now owns 1,511 shares in the company, valued at approximately $749,456. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brian S. Tyler sold 3,473 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the sale, the chief executive officer now owns 43,445 shares of the company’s stock, valued at approximately $22,789,074.75. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MCK shares. StockNews.com downgraded McKesson from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 4th. Citigroup raised their price target on McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a research report on Thursday, February 8th. UBS Group raised their price target on McKesson from $575.00 to $620.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Argus raised their price target on McKesson from $510.00 to $570.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Finally, Mizuho lifted their target price on McKesson from $450.00 to $505.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $533.50.

McKesson Price Performance

Shares of NYSE:MCK traded up $0.35 during trading on Friday, reaching $519.16. The stock had a trading volume of 75,162 shares, compared to its average volume of 681,007. McKesson Co. has a 52 week low of $352.34 and a 52 week high of $543.00. The business’s 50-day moving average price is $524.44 and its 200 day moving average price is $485.71. The stock has a market capitalization of $68.22 billion, a PE ratio of 23.51, a P/E/G ratio of 1.43 and a beta of 0.45.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $7.74 earnings per share for the quarter, topping the consensus estimate of $7.05 by $0.69. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The firm had revenue of $80.90 billion during the quarter, compared to analysts’ expectations of $77.93 billion. During the same quarter in the previous year, the company posted $6.90 EPS. McKesson’s revenue was up 14.8% on a year-over-year basis. Analysts forecast that McKesson Co. will post 27.59 EPS for the current year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 1st. Investors of record on Friday, March 1st were given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 0.48%. The ex-dividend date was Thursday, February 29th. McKesson’s dividend payout ratio (DPR) is presently 11.24%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.